Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024

Contributed by: Business Wire

Logo

Tags

Biotechnology

Technology

Health

Pharmaceutical

Oncology

Health Technology

Research

Artificial Intelligence

Genetics

Science

Clinical Trials

LSD1 and MALT1 inhibitors

More Like This

Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ESMO 2023

Exscientia Initiates Clinical Study to Further Evaluate Functional Precision Medicine Platform in Cancer Patients

Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout

Exscientia Announces Expansion of its Current Collaboration with Sanofi to Include Existing Exscientia Programme

Exscientia to Present at Upcoming Investor Conferences in June

GlobeNewswire associated0

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration

Exscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference